Call Us
+1-866-935-5383
Our Location
Dallas Texas
+1-866-935-5383
Dallas Texas
Tirzepatide Pharma Corporation (previously known as Bachem Pharma)—a leading, innovation-driven company specializing in the development and manufacture of peptides, peptide drugs, and oligonucleotides. The company, with over 30 years of experience and expertise, provides products for research, clinical development, and commercial applications to pharmaceutical and biotechnology companies worldwide, offering a comprehensive range of services. The company serves clients across the world, emphasizing its strong international presence and global reach. Bio-Pharma operates internationally from Switzerland to Europe, the USA, and Asia.
Additionally. Tirzepatide Pharma Corporation has developed proprietary technology platforms for the development and manufacturing of peptides, lipids, carbohydrates, and proteins, supporting a wide range of pharmaceutical projects. The company offers custom peptides tailored to specific client requirements, including rare modifications and complex sequences. Its contract manufacturing and contract manufacturing services enable large-scale and efficient production of peptide APIs and biologics. Clients benefit from outsourcing to Tirzepatide Pharma Corporation, gaining access to advanced technology, scalability, and full compliance with cGMP standards. The company supports clients through all phases of drug development, from early research to clinical trials, ensuring efficient progression through the clinical trial phases. Each project is managed comprehensively, from initial research through scale-up, validation, and commercialization.
Tirzepatide Pharma Corporation has developed optimized production processes to ensure high purity and efficiency. The company can efficiently scale production processes from small scale laboratory or pilot batches to full production scale. Its expertise in process development and process qualification ensures robust, validated manufacturing workflows that meet regulatory requirements. Efficient management of raw materials and reagents helps reduce production costs and improve the efficiency of peptide API synthesis. The company is focused on cost reduction through innovative technologies and integrated processes. Tirzepatide Pharma Corporation handles both APIs and finished drug products in various form, including injectable formulations, within a fully integrated supply chain. Expected growth and capacity expansion plans position the company for future leadership in the industry. The company’s peptide APIs target a range of therapeutic areas, including metabolic disorders, and are used in the treatment of various medical conditions. Comprehensive studies and analyses have been conducted by the company to maintain industry expertise and support ongoing innovation.
The GMP site in Garland, Texas, was renamed to Tirzepatide firm (Pharm) in 2005. It is the clean room center of excellence for our organization in the development of new chemical entities (NCEs), with in-depth knowledge and expertise in chemistry, manufacturing, and controls (CMC) to achieve successful commercialization. Together with state-of-the-art equipment and a rapidly growing degree of automation, the Garland site delivers efficient peptide active pharmaceutical ingredient (API) development and manufacturing on both small scale and production scale, supporting a wide range of batch sizes.
The site specializes in process development and process qualification, ensuring regulatory compliance and efficient workflows for peptide and protein manufacturing. Advanced equipment and automation enable optimized production processes, with careful management of raw materials and reagents to maximize efficiency and product quality. The site’s manufacturing operations are designed to reduce cost, making production more economical for clients. All processes have been developed to achieve high efficiency and quality standards. The Garland site manufactures APIs in various form, including lyophilized powders and solutions, to meet diverse drug delivery and stability requirements.
The current management is a trio of former Pfizer bioengineers specializing in the development of new vaccine products, now merging with RapheGenerics Biopharmaceutical Company to create a better well-being for all. The team brings extensive experience in managing complex project initiatives, overseeing peptide development from early research through scale-up and regulatory approval. They have also conducted comprehensive analyses of the peptide synthesis market, demonstrating their industry expertise. Our mission is to support clients throughout the drug development process, from research to commercialization, by offering high-quality products that enhance well-being, research-grade items, and solutions for non-GMP product requirements. We design custom peptides tailored to your precise specifications, accommodating any scale from milligrams to kilograms and tons. Our future plans are expected to drive further growth and expand our capabilities. We support clients through all phases of clinical trials, ensuring efficient progression through the development pipeline. Our products target a range of therapeutic areas, including the treatment of metabolic disorders, to improve patient outcomes.
Our company has no affiliation with Bachem AG or Pfizer and should not be misinterpreted as such.
Peptide synthesis is a foundational process in the pharmaceutical industry, enabling the creation of peptides—short chains of amino acids linked by peptide bonds—that serve as the building blocks for a wide range of therapeutics. This process is essential for producing peptide APIs, which are critical in the development of treatments for metabolic and oncological disorders. Peptide synthesis can be achieved through various methods, with solid-phase and solution-phase synthesis being the most widely used. Each method offers unique advantages in terms of efficiency, scalability, and purity, making them suitable for different stages of peptide development and production. As the demand for peptide-based therapeutics continues to rise, pharmaceutical and biotech companies increasingly rely on specialized peptide synthesis services to support their research, clinical development, and commercial production needs.
Peptide APIs, or active pharmaceutical ingredients, play a pivotal role in the advancement of modern therapeutics, particularly in addressing complex metabolic and oncological disorders. The manufacturing of peptide APIs involves sophisticated peptide synthesis techniques, such as solid-phase and solution-phase methods, to ensure high purity and efficacy. These APIs are integral to the development of innovative treatments, ranging from rare disease therapies to next-generation cancer drugs. As the pharmaceutical and biotech industries recognize the therapeutic potential of peptides, there is a growing investment in peptide API manufacturing. Companies are expanding their capabilities to meet the increasing demand for high-quality peptide APIs, supporting the development and commercialization of new, life-changing therapeutics.
Analytical development is a crucial component of peptide manufacturing, ensuring that each peptide API meets stringent quality and efficacy standards. This stage involves the creation and validation of advanced analytical methods, such as high-performance liquid chromatography (HPLC) and mass spectrometry, to monitor the production process and detect any impurities. By implementing robust analytical development strategies, pharmaceutical companies can guarantee the consistency, purity, and safety of their peptide APIs. Investing in state-of-the-art analytical technologies is essential for supporting peptide development and manufacturing, enabling companies to deliver reliable and effective peptide products to the market.
GMP manufacturing is fundamental to the production of high-quality peptide APIs, ensuring that every step of the manufacturing process adheres to strict regulatory standards. Compliance with Good Manufacturing Practices involves rigorous quality control, meticulously maintained facilities, and comprehensive training for all personnel involved in peptide development and production. Pharmaceutical companies must invest in GMP-compliant manufacturing processes and facilities to support the successful commercialization of peptide-based therapeutics. By prioritizing GMP standards, companies can ensure the safety, efficacy, and reliability of their peptide APIs, meeting both regulatory requirements and the expectations of healthcare providers and patients.
In summary, peptide production is a sophisticated and highly regulated process that demands specialized expertise, advanced technologies, and dedicated facilities. The increasing demand for peptide APIs in the pharmaceutical and biotech sectors underscores the need for robust peptide development, analytical development, and GMP-compliant manufacturing. By investing in these critical areas and partnering with experienced contract manufacturers, pharmaceutical companies can accelerate the development and commercialization of innovative peptide therapeutics. This approach not only ensures the efficient production of high-quality peptide APIs but also helps bring new treatments to market, ultimately improving patient outcomes worldwide.